Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | RXRB | P28702 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8833698 | 0.88 | ALOX5 (0.62) | ALOX5MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL2885897 | 0.88 | ALOX5 (0.62) | ALOX5MAOBNR4A1NR4A2NR4A3 | |
| Hydrochloric Acid SCHEMBL6948842 | 0.86 | ALOX5 (0.60) | ALOX5MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL2170633 | 0.85 | ALOX5 (0.67) | ALOX5MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL9577464 | 0.85 | ALOX5 (0.59) | ALOX5MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL6266373 | 0.84 | LTA4H (0.59) | ALOX5MAOBLMNAL3MBTL1ACACB | |
| SCHEMBL28353364 | 0.84 | MRGPRX4 (0.59) | ALOX5MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL27733432 | 0.83 | NR4A1 (0.57) | ALOX5MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL7401422 | 0.82 | LMNA (0.71) | ALOX5MAOBNR4A1NR4A2NR4A3 | |
| SCHEMBL10867537 | 0.82 | LMNA (0.70) | ALOX5MAOBNR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704117-B1 | AZABICYCLO DERIVATIVES FOR TREATING OCULAR DISORDERS | ALCON INC (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12247028-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2025-03-11 | — | — | US | disclosed |
| US-20240132497-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2024-04-25 | — | — | US | disclosed |
| US-11884666-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2024-01-30 | — | — | US | disclosed |
| US-20220267328-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2022-08-25 | — | — | US | disclosed |
| US-11306090-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20210179616-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2021-06-17 | — | — | US | disclosed |
| US-20210179616-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2021-06-17 | — | — | US | disclosed |
| EP-3704117-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES FOR TREATING OCULAR DISORDERS | ALCON INC. (CH) | 2020-09-09 | — | — | EP | disclosed |
| CN-111247147-A | Azabicyclo and diazepatriene derivatives useful for treating ocular disorders | 爱尔康公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-0936218-B1 | BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARM CO LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6387938-B1 | Benzimidazole derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-5952390-A | ANTIINFLAMMATORY AGENTS; TREATMENT FOR PSORIASIS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1999-09-14 | — | — | US | disclosed |
| EP-0936218-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-18 | — | — | EP | disclosed |
| US-5844004-A | 10-substituted 1,8-dihydroxy-9 (10H) anthracenone pharmaceuticals | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1998-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884666-B2 | Azabicyclo and diazepine derivatives | CHRM3, CHRM5, CHRNA5 | ALOX5 867/4885MAOB 376/4885NR4A1 236/4885 |
| US-20240132497-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | CHRM3, CHRM5, CHRNA5 | ALOX5 867/4885MAOB 376/4885NR4A1 236/4885 |
| US-20210179616-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | CHRM3, CHRM5, CHRNA5 | ALOX5 867/4885MAOB 376/4885NR4A1 236/4885 |
| US-20220267328-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | CHRM3, CHRM5, CHRNA5 | ALOX5 867/4885MAOB 376/4885NR4A1 236/4885 |
| US-12247028-B2 | Azabicyclo and diazepine derivatives | CHRM3, CHRM5, CHRNA5 | ALOX5 867/4885MAOB 376/4885NR4A1 236/4885 |
| US-11306090-B2 | Azabicyclo and diazepine derivatives | CHRM3, CHRM5, CHRNA5 | ALOX5 867/4885MAOB 376/4885NR4A1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.